CERAMENT®: The Bone Healing
eröffnet am 29.09.20 18:32:25 von
neuester Beitrag 26.04.24 11:52:21 von
neuester Beitrag 26.04.24 11:52:21 von
Beiträge: 93
ID: 1.331.602
ID: 1.331.602
Aufrufe heute: 0
Gesamt: 8.900
Gesamt: 8.900
Aktive User: 0
ISIN: SE0009858152 · WKN: A2DTSD · Symbol: 2B4
19,810
EUR
-2,12 %
-0,430 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0500 | +112,88 | |
| 1,2200 | +44,38 | |
| 5,2900 | +38,85 | |
| 14,830 | +34,09 | |
| 3,0300 | +32,89 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7500 | -12,79 | |
| 0,6450 | -14,00 | |
| 0,5051 | -14,39 | |
| 27,53 | -15,29 | |
| 2,0500 | -28,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Gibt es hier noch einmal einen Rücksetzer oder ist es schon zu spät? Scheint eine interessante Firma zu sein:-).
https://bonezonepub.com/2024/02/20/5-innovative-companies-ar…
Viel Erfolg
SmallCap
https://bonezonepub.com/2024/02/20/5-innovative-companies-ar…
Viel Erfolg
SmallCap
CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES
Published: 2024-03-05
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, announces that the company’s 510 (k) submission for CERAMENT BONE VOID FILLER to include Spine Interbody Fusion procedure has been cleared by the FDA. As previously informed, a market introduction in the spine segment could take place at the end of 2025.
https://www.bonesupport.com/en-eu/media/press-releases/ceram…
20 Euro 😍
https://www.bonesupport.com/en-eu/media/press-releases/bones…
"BONESUPPORT, ein führendes Unternehmen im Bereich Orthobiologie zur Behandlung von Knochenverletzungen, gibt heute bekannt, dass das Unternehmen die CE-Zertifizierung für seine Produkte CERAMENT BONE VOID FILLER und CERAMENT V gemäß der neuen EU-MDR (EU MDR 2017/745) erhalten hat . Die EU-Medizinprodukteverordnung wurde eingeführt, um die Messlatte für Qualität und Sicherheit von Medizinprodukten in Europa weiter anzuheben. BONESUPPORT hat bereits die MDR-Zertifizierung für CERAMENT ® G und das Qualitätsmanagementsystem erhalten. Dabei ist das gesamte Produktportfolio MDR-zertifiziert."
"BONESUPPORT, ein führendes Unternehmen im Bereich Orthobiologie zur Behandlung von Knochenverletzungen, gibt heute bekannt, dass das Unternehmen die CE-Zertifizierung für seine Produkte CERAMENT BONE VOID FILLER und CERAMENT V gemäß der neuen EU-MDR (EU MDR 2017/745) erhalten hat . Die EU-Medizinprodukteverordnung wurde eingeführt, um die Messlatte für Qualität und Sicherheit von Medizinprodukten in Europa weiter anzuheben. BONESUPPORT hat bereits die MDR-Zertifizierung für CERAMENT ® G und das Qualitätsmanagementsystem erhalten. Dabei ist das gesamte Produktportfolio MDR-zertifiziert."
KAPITALMARKTTAG 2023
https://ir.financialhearings.com/bonesupport-cmd-2023"BONESUPPORT veranstaltete am Dienstag, den 28. November 2023, einen Capital Markets Day (CMD), der Investoren, Analysten und Medienvertreter zusammenbrachte. Im Mittelpunkt des CMD stand die Veröffentlichung eines Updates zur Strategie und Entwicklung von BONESUPPORT. Der Schwerpunkt des Tages lag auf der spannenden Innovationslandschaft. Bei der Veranstaltung gab das Unternehmen auch einen aktualisierten Ausblick für 2024 mit einem Umsatzwachstum von über 40 Prozent."
Trading Spotlight
BONESUPPORT HOLDING AB (publ) – Publishes Q3 2023 interim report
Published: 2023-10-26
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2023.
CONTINUED STRONG GROWTH IN BOTH SEGMENTS
JULY – SEPTEMBER 2023
Net sales increased by 87 percent (76 percent at constant exchange rates) and amounted to SEK 158.2 million (84.6).
The North America (NA) segment reported a sales growth of 115 percent (102 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
The gross margin amounted to 92.1 percent (90.8).
The operating result before effects from the Group’s incentive programs amounted to SEK +24.6 million (-4.4). Reported operating result amounted to SEK +14.9 million (-13.9).
Earnings per share before dilution were SEK +3.52 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.18.
Earnings per share after dilution were SEK +3.47 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.18.
JANUARY – SEPTEMBER 2023
Net sales increased by 85 percent (75 percent at constant exchange rates) and amounted to SEK 418.3 million (225.6).
The North America (NA) segment reported a sales growth of 117 percent (103 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
The gross margin amounted to 91.4 percent (90.1)
The operating result before effects from the Group’s incentive programs amounted to SEK +42.8 million (-26.1). Reported operating result amounted to SEK +21.6 million (-45.3).
Earnings per share before dilution were SEK +3.61 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.26.
Earnings per share after dilution were SEK +3.56 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.26.
"87 percent sales growth and the first quarter with positive cash flow." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
During August, the last patient was enrolled to the SOLARIO study.
During the quarter, the Company recognized deferred tax receivables on its tax losses carried forward in the balance sheet for the first time, amounting to SEK 230 million.
EVENTS AFTER THE REPORTING PERIOD
In October 2023, BONESUPPORT received Breakthrough device designation from the FDA for CERAMENT V for the indication of bone infection.
https://www.bonesupport.com/en-eu/media/press-releases/bones…
Published: 2023-10-26
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2023.
CONTINUED STRONG GROWTH IN BOTH SEGMENTS
JULY – SEPTEMBER 2023
Net sales increased by 87 percent (76 percent at constant exchange rates) and amounted to SEK 158.2 million (84.6).
The North America (NA) segment reported a sales growth of 115 percent (102 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
The gross margin amounted to 92.1 percent (90.8).
The operating result before effects from the Group’s incentive programs amounted to SEK +24.6 million (-4.4). Reported operating result amounted to SEK +14.9 million (-13.9).
Earnings per share before dilution were SEK +3.52 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.18.
Earnings per share after dilution were SEK +3.47 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.18.
JANUARY – SEPTEMBER 2023
Net sales increased by 85 percent (75 percent at constant exchange rates) and amounted to SEK 418.3 million (225.6).
The North America (NA) segment reported a sales growth of 117 percent (103 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
The gross margin amounted to 91.4 percent (90.1)
The operating result before effects from the Group’s incentive programs amounted to SEK +42.8 million (-26.1). Reported operating result amounted to SEK +21.6 million (-45.3).
Earnings per share before dilution were SEK +3.61 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.26.
Earnings per share after dilution were SEK +3.56 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.26.
"87 percent sales growth and the first quarter with positive cash flow." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
During August, the last patient was enrolled to the SOLARIO study.
During the quarter, the Company recognized deferred tax receivables on its tax losses carried forward in the balance sheet for the first time, amounting to SEK 230 million.
EVENTS AFTER THE REPORTING PERIOD
In October 2023, BONESUPPORT received Breakthrough device designation from the FDA for CERAMENT V for the indication of bone infection.
https://www.bonesupport.com/en-eu/media/press-releases/bones…
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2023.
STRONG MOMENTUM FOR CERAMENT G IN THE US
APRIL – JUNE 2023
Net sales increased by 88 percent (75 percent at constant exchange rates) and amounted to SEK 140.4 million (74.6).
The North America (NA) segment reported a sales growth of 126 percent (107 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (24 percent at constant exchange rates).
The gross margin amounted to 91.3 percent (89.0).
Operating result before effects from the Group’s incentive programs amounted to SEK +13.6 million (-9.1). Reported operating result amounted to SEK +6.0 million (-14.9).
Earnings per share before dilution were SEK +0.08 (-0.25).
Earnings per share after dilution were SEK +0.08 (-0.25).
JANUARY – JUNE 2023
Net sales increased by 85 percent (72 percent at constant exchange rates) and amounted to SEK 260.1 million (141.0).
The North America (NA) segment reported a sales growth of 118 percent (100 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (27 percent at constant exchange rates).
The gross margin amounted to 90.9 percent (89.7)
Operating result before effects from the Group’s incentive programs amounted to SEK +18.2 million (-21.6). Reported operating result amounted to SEK +6.7 million (-31.3).
Earnings per share before dilution were SEK +0.09 (-0.51).
Earnings per share after dilution were SEK +0.08 (-0.51).
"Strong quarter, with increased market penetration for CERAMENT G." Emil Billbäck, CEO
https://www.bonesupport.com/en-eu/media/press-releases/bones…
STRONG MOMENTUM FOR CERAMENT G IN THE US
APRIL – JUNE 2023
Net sales increased by 88 percent (75 percent at constant exchange rates) and amounted to SEK 140.4 million (74.6).
The North America (NA) segment reported a sales growth of 126 percent (107 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (24 percent at constant exchange rates).
The gross margin amounted to 91.3 percent (89.0).
Operating result before effects from the Group’s incentive programs amounted to SEK +13.6 million (-9.1). Reported operating result amounted to SEK +6.0 million (-14.9).
Earnings per share before dilution were SEK +0.08 (-0.25).
Earnings per share after dilution were SEK +0.08 (-0.25).
JANUARY – JUNE 2023
Net sales increased by 85 percent (72 percent at constant exchange rates) and amounted to SEK 260.1 million (141.0).
The North America (NA) segment reported a sales growth of 118 percent (100 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (27 percent at constant exchange rates).
The gross margin amounted to 90.9 percent (89.7)
Operating result before effects from the Group’s incentive programs amounted to SEK +18.2 million (-21.6). Reported operating result amounted to SEK +6.7 million (-31.3).
Earnings per share before dilution were SEK +0.09 (-0.51).
Earnings per share after dilution were SEK +0.08 (-0.51).
"Strong quarter, with increased market penetration for CERAMENT G." Emil Billbäck, CEO
https://www.bonesupport.com/en-eu/media/press-releases/bones…
BONESUPPORT HOLDING AB (publ) – Publishes Q1 2023 interim report
Published: 2023-04-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.
CONTINUED STRONG GROWTH
JANUARY – MARCH 2023
Net sales increased by 80 percent (66 percent at constant exchange rates) and amounted to SEK 119.7 million (66.3).
The North America (NA) segment reported a sales growth of 109 percent (87 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 34 percent (32 percent at constant exchange rates).
The gross margin amounted to 90.5 percent (90.5).
Operating result before effects from the Group’s incentive programs amounted to SEK +4.6 million (-12.5). Reported operating result amounted to SEK +0.8 million (-16.5).
Earnings per share, before and after dilution, were SEK +0.00 (-0.32).
"Strong sales growth driven by CERAMENT G in the US." Emil Billbäck, CEO
https://www.bonesupport.com/en-eu/media/press-releases/bones…
Published: 2023-04-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.
CONTINUED STRONG GROWTH
JANUARY – MARCH 2023
Net sales increased by 80 percent (66 percent at constant exchange rates) and amounted to SEK 119.7 million (66.3).
The North America (NA) segment reported a sales growth of 109 percent (87 percent at constant exchange rate).
The Europe & Rest of the World (EUROW) segment reported a sales growth of 34 percent (32 percent at constant exchange rates).
The gross margin amounted to 90.5 percent (90.5).
Operating result before effects from the Group’s incentive programs amounted to SEK +4.6 million (-12.5). Reported operating result amounted to SEK +0.8 million (-16.5).
Earnings per share, before and after dilution, were SEK +0.00 (-0.32).
"Strong sales growth driven by CERAMENT G in the US." Emil Billbäck, CEO
https://www.bonesupport.com/en-eu/media/press-releases/bones…
Der Kurs hat sich ja sehr erfreulich entwickelt. Hatte damals beim Absturz eine kleine Position gekauft und bin mittlerweile bei +80%.
Zu hart bestraft..
am 04. kommen Q3, die Chance für einen kleinen Anstieg ist durchaus gegeben in Anbetracht des jetzigen Niveaus. „KNOCHEN-UNTERSTÜTZUNG: TEILE ZU HART BEHANDELT TROTZ Enttäuschungen - SEB
STOCKHOLM (Nyhetsbyrån Direkt) Auch angesichts der jüngsten Enttäuschungen, bei denen die Ergebnisse der Fortify-Studie des Unternehmens nicht eindeutig waren, wurde die Aktie von Bonesupport zu hart behandelt.
SEB Equities glaubt dies in einer Analyse, in der die Empfehlung für das Medizintechnikunternehmen angehoben wird, aus der Warteschleife zu kaufen, während das Kursziel von 60 SEK auf 58 gesenkt wird, worüber Nyhetsbyrån Direkt am Donnerstag zuvor berichtete.
SEB weist unter anderem darauf hin, dass der Antrag von Bonesupport für Cerament G bei Knocheninfektionen nach Plan verläuft und sich für eine mögliche sogenannte De Novo-Zulassung im ersten Quartal 2022 öffnet. Zudem besteht Nachholbedarf bei orthopädischen Verfahren im Zuge der Pandemie dürfte das Wachstum des Unternehmens in den kommenden Jahren unterstützen, während Bonesupport über eine stabile Liquiditätsposition verfügt.
Bonesupport veröffentlicht am 4. November seinen nächsten Zwischenbericht. SEB erwartet für das dritte Quartal ein organisches Wachstum von rund 18 Prozent gegenüber dem entsprechenden Vorjahreszeitraum. Es wird erwartet, dass sich die Delta-Variante negativ auf Bonesupport ausgewirkt hat, jedoch mit einer allmählichen Verbesserung der Position gegen Ende des Quartals.
Der Anteil der Knochenunterstützung stieg am Donnerstagmorgen an der Stockholmer Börse um knapp über 6 Prozent auf knapp 38 SEK um 9.50 Uhr. In den letzten drei Monaten hat Bonesupport jedoch 52 Prozent verloren.”
Durchsuchen
